Skip to Content
Menu
About
Science
EDO Platform
Scientific Publications
Pipeline
Overview
Clinical Trials
Expanded Access Policy
Community
Community Stories
DMD
DM1
Careers
Investors
News
Contact
Mechanistic Characterization of Enhanced Delivery Oligonucleotide (EDO) Platform
Post navigation
Previous:
Single- and Repeat-Dose Nonclinical Data for PGN-EDO51 Demonstrated Favorable Pharmacology and Safety Profiles for the Treatment of DMD
Next:
FREEDOM-DM1: A Phase 1, Placebo-Controlled Single Ascending Dose Study to Evaluate PGN-EDODM1 in People with Myotonic Dystrophy Type 1 (DM1)
